Yazar "Yurdaydin, C" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Famciclovir treatment of chronic delta hepatitis(Elsevier Science Bv, 2002) Yurdaydin, C; Bozkaya, H; Gürel, S; Tillmann, HL; Aslan, N; Okçu-Heper, A; Erden, EBackground/Aims: Interferon is the only established therapy for chronic delta hepatitis and alternative treatment options are an urgent need. Since successful treatment of a case of post-transplant delta hepatitis with the nucleoside analogue famciclovir had been reported, a pilot study was undertaken to evaluate the use of famciclovir in the treatment of chronic delta hepatitis. Methods: A total of 15 adult patients, 13 men, two women, ages 20-52 years, with chronic delta hepatitis were treated with famciclovir, 500 mg, three times a day for 6 months and were then followed-up for 6 months posttreatment. All patients had compensated chronic liver disease, elevated liver enzymes and were hepatitis delta virus (HDV) RNA positive by polymerase chain reaction at baseline. Patients were monitored and tested for HBsAg, hepatitis B virus (HBV) DNA and HDV RNA levels. Liver biopsies were obtained before starting famciclovir and within I month of completion of treatment. Results: HBV DNA levels decreased in nine of the 15 patients and levels rose again after treatment (P < 0.05). Famciclovir had no effect on alanine aminotransferase (ALT) and HBsAg levels or on serum HDV RNA and overall, there was no improvement in liver histology. Conclusions: Treatment of chronic delta hepatitis with famciclovir has no effect on disease activity and HDV RNA levels. (C) 2002 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.Öğe Risk factors for hepatocellular carcinoma in Turkey(Springer, 2001) Uzunalimoglu, Ö; Yurdaydin, C; Çetinkaya, H; Bozkaya, H; Sahin, T; Çolakoglu, S; Tankurt, EThe contribution of hepatitis B, hepatitis C, and excess alcohol intake to the development of hepatocellular carcinoma in Turkey was assessed. The study was conducted through a questionnaire sent to seven major medical referral centers in different regions of Turkey and is based on 207 patients seen in the period 1994-1997. Of the seven centers, two were located in West Turkey (54 patients), two were in Central Turkey (85 patients), and two were in south and southeast Turkey (68 patients). In 196 of the 207 patients (94.7%), there was a history of chronic liver disease, and in 180 patients (87%) liver cirrhosis was documented, Of the 207 patients, 116 (56%) had hepatitis B, 48 (23.2%) had hepatitis C and 33 (15.9%) had a history of excess alcohol intake. Anti-delta testing was available in 69 of 116 patients with hepatitis B, and anti-HDV was positive in 13 of these patients (13/69, 18.8%). Of the 33 patients with a history of heavy alcohol intake, 18 had concomitant chronic viral hepatitis infection, and alcohol alone was the etiology of hepatocellular carcinoma in only 15 cases (7.2%). The distribution of etiologic factors was not homogenous in different geographical regions ill Turkey. In central, south, and southeastern Turkey, the predominant etiology of hepatocellular carcinoma was hepatitis B, whereas in western Turkey the impact of hepatitis B, hepatitis C, and alcohol was similar. This study indicates that hepatitis B virus infection is the leading cause of hepatocellular carcinoma in Turkey, followed by hepatitis C infection and alcoholic liver disease.Öğe The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during ?-interferon therapy(Lippincott Williams & Wilkins, 2003) Yalcin, K; Degertekin, H; Yurdaydin, C; Bozdayi, M; Bozkaya, H[Abstract Not Available]Öğe Treatment of chronic hepatitis D with famciclovir(Elsevier, 2000) Yurdaydin, C; Bozkaya, H; Gürel, S; Erkan, Ö; Erden, E; Memik, F; Degertekin, H[Abstract Not Available]
